Literature DB >> 30046318

Activating natural killer (NK) cytotoxicity of canine CD5-CD21- cells requires low surface CD5 density NK cells.

C S Lin1,2, C P Chang1, H C Chiang1,2, T F Chuang2, C H Hsu1, C C Liu1.   

Abstract

Natural killer (NK) cells play a crucial role in regulating immune functions. Few studies have characterized canine NK cells. We previously demonstrated that canine peripheral blood lymphocytes (PBLs) with a low surface CD5 density (CD5lo) are considered a critical NK population. Natural killer cells in most mammals do not express T-cell markers, but canine CD5lo cells express surface molecules, such as CD3 T-cell receptors. These features make canines unique models for the study of comparative immunology in NK cells. In this study, we discovered that CD5lo and CD21 double-negative (CD5lo-ne/CD2-) cells were originally low in NK cytotoxicity and their NK cytotoxicity was highly activated when co-cultured with CD5lo NK cells. The cytotoxicity was not activated when co-cultured with other cell types, such as high surface CD5 density (CD5hi) cells. The CD5lo-negative (CD5lo-ne) population comprises CD5- and CD5hi cells. CD5-cells were low in NK cytotoxicity initially or after culturing with interleukin-2 (IL-2) without CD5lo cells; however, the addition of CD5lo cells in a similar medium markedly enhanced the NK activity. By contrast, CD5hi cells were always NK inactive, irrespective of them being cultured with CD5lo cells or not. We further verified that only the CD5-CD21- cells, which were separated from CD5-CD21+ cells in the entire CD5- population, showed activated NK activity through CD5lo cell induction. This study is the first to reveal that canine NK cells enhanced NK-inert cells to become NK-cytotoxic cells. Additionally, it is concluded that in beagles, except for CD5lo cells, CD5-CD21- cells show NK activity.

Entities:  

Keywords:  CD5−CD21− cells; Cytotoxicity; Low surface CD5 density; Natural killer cells

Year:  2018        PMID: 30046318      PMCID: PMC6056148     

Source DB:  PubMed          Journal:  Iran J Vet Res        ISSN: 2252-0589            Impact factor:   1.376


  22 in total

1.  CTLA-4 is expressed by activated mouse NK cells and inhibits NK Cell IFN-γ production in response to mature dendritic cells.

Authors:  Ana Stojanovic; Nathalie Fiegler; Monika Brunner-Weinzierl; Adelheid Cerwenka
Journal:  J Immunol       Date:  2014-03-31       Impact factor: 5.422

2.  Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells.

Authors:  Aimee C Talleur; Brandon M Triplett; Sara Federico; Ewelina Mamcarz; William Janssen; Jianrong Wu; David Shook; Wing Leung; Wayne L Furman
Journal:  Biol Blood Marrow Transplant       Date:  2017-07-18       Impact factor: 5.742

3.  Synergistic effects of prolonged warm ischemia and donor age on the immune response following donation after cardiac death kidney transplantation.

Authors:  Christian Denecke; Xiaodong Yuan; Xupeng Ge; Irene K Kim; Daman Bedi; Olaf Boenisch; Anne Weiland; Anke Jurisch; Katja Kotsch; Johann Pratschke; Anja Reutzel-Selke; Stefan G Tullius
Journal:  Surgery       Date:  2012-10-09       Impact factor: 3.982

4.  Measurement of NK activity in effector cells purified from canine peripheral lymphocytes.

Authors:  D W Knapp; R R Leibnitz; D B DeNicola; J J Turek; R Teclaw; L Shaffer; T C Chan
Journal:  Vet Immunol Immunopathol       Date:  1993-01       Impact factor: 2.046

5.  Gene-expression profiling to identify genes related to spontaneous tumor regression in a canine cancer model.

Authors:  Hsin-Chien Chiang; Albert Tai-Ching Liao; Tong-Rong Jan; Yu-Shan Wang; Han-Jung Lei; Mong-Hsun Tsai; Mo-Fen Chen; Chien-Yueh Lee; Yi-Chen Lin; Rea-Min Chu; Chen-Si Lin
Journal:  Vet Immunol Immunopathol       Date:  2012-11-21       Impact factor: 2.046

Review 6.  Human natural killer cell deficiencies.

Authors:  Jordan S Orange
Journal:  Curr Opin Allergy Clin Immunol       Date:  2006-12

7.  Tumor-infiltrating lymphocyte secretion of IL-6 antagonizes tumor-derived TGF-beta 1 and restores the lymphokine-activated killing activity.

Authors:  Ya-Wen Hsiao; Kuang-Wen Liao; Shao-Wen Hung; Rea-Min Chu
Journal:  J Immunol       Date:  2004-02-01       Impact factor: 5.422

8.  CD5-low expression lymphocytes in canine peripheral blood show characteristics of natural killer cells.

Authors:  Yi-Chun Huang; Shao-Wen Hung; Tong-Rong Jan; Kuang-Wen Liao; Chiung-Hsiang Cheng; Yu-Shan Wang; Rea-Min Chu
Journal:  J Leukoc Biol       Date:  2008-08-15       Impact factor: 4.962

9.  Hydrocortisone prevents immunosuppression by interleukin-10+ natural killer cells after trauma-hemorrhage.

Authors:  Antoine Roquilly; Alexis Broquet; Cédric Jacqueline; Damien Masson; Jean Pierre Segain; Cecile Braudeau; Mickael Vourc'h; Jocelyne Caillon; Frédéric Altare; Regis Josien; Christelle Retière; Jose Villadangos; Karim Asehnoune
Journal:  Crit Care Med       Date:  2014-12       Impact factor: 7.598

10.  Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.

Authors:  Jennifer N Brudno; Robert P T Somerville; Victoria Shi; Jeremy J Rose; David C Halverson; Daniel H Fowler; Juan C Gea-Banacloche; Steven Z Pavletic; Dennis D Hickstein; Tangying L Lu; Steven A Feldman; Alexander T Iwamoto; Roger Kurlander; Irina Maric; Andre Goy; Brenna G Hansen; Jennifer S Wilder; Bazetta Blacklock-Schuver; Frances T Hakim; Steven A Rosenberg; Ronald E Gress; James N Kochenderfer
Journal:  J Clin Oncol       Date:  2016-01-25       Impact factor: 44.544

View more
  1 in total

Review 1.  Characterization and Potential Applications of Dog Natural Killer Cells in Cancer Immunotherapy.

Authors:  Alicia A Gingrich; Jaime F Modiano; Robert J Canter
Journal:  J Clin Med       Date:  2019-10-27       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.